Effect of alemtuzumab or basiliximab induction therapy on graft function and survival of kidneys from donors after cardiac death

Transplant International

Volumn 22, Issue 10, 2009, Pages 1024-1027

  Plata Munoz, Juan J ^a,b   Vaidya, Anil ^b   Fuggle, Susan V ^a,b   Friend, Peter J ^a,b  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALEMTUZUMAB; BASILIXIMAB; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISOLONE; RAPAMYCIN; TACROLIMUS; THYMOCYTE ANTIBODY;

ADULT; AGED; BK VIRUS; BREAST CANCER; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOMEGALOVIRUS INFECTION; DELAYED GRAFT FUNCTION; EPSTEIN BARR VIRUS; FEMALE; GRAFT SURVIVAL; HEART DEATH; HEPATITIS C; HUMAN; HUMAN TISSUE; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; LETTER; LYMPHOCYTIC INFILTRATION; LYMPHOPROLIFERATIVE DISEASE; MALE; PRIORITY JOURNAL; RETROPERITONEAL HEMORRHAGE; SKIN CANCER; URETER OBSTRUCTION; UROSEPSIS; VIRUS INFECTION;

ADOLESCENT; ADULT; AGED; ANTIBODIES, MONOCLONAL; ANTIBODIES, NEOPLASM; DEATH; FEMALE; GRAFT REJECTION; GRAFT SURVIVAL; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; LYMPHOCYTE COUNT; LYMPHOCYTES; MALE; MIDDLE AGED; RECOMBINANT FUSION PROTEINS; TRANSPLANTATION CONDITIONING; TREATMENT OUTCOME;

EID: 69949132516     PISSN: 09340874     EISSN: 14322277     Source Type: Journal    
DOI: 10.1111/j.1432-2277.2009.00910.x     Document Type: Letter

References (8)

1. Schadde E, D'Alessandro AM, Knechtle SJ, et al. Alemtuzumab induction and triple maintenance immunotherapy in kidney transplantation from donors after cardiac death. Transpl Int 2008 21 : 625.
2. + T cell as a major pathogenic factor in ischemic acute renal failure. J Clin Invest 2001 108 : 1283.
3. Gandolfo MT, Rabb H. Very early alloantigen-independent trafficking of lymphocytes during ischemic acute kidney injury. Kidney Int 2007 71 : 1193.
4. Kootstra G, Daemen JH, Oomen AP. Categories of non-heart-beating donors. Transplant Proc 1995 27 : 2893.
5. Plata-Munoz JJ, Muthusamy A, Quiroga I, et al. Impact of pulsatile perfusion on postoperative outcome of kidneys from controlled donors after cardiac death. Transpl Int, 2008 21 : 899.
6. Kirk AD, Hale DA, Mannon RB, et al. Results from a human renal allograft tolerance trial evaluating the humanized CD52-specific monoclonal antibody alemtuzumab (CAMPATH-H1). Transplantation 2003 76 : 120.
7. Trzonkowski P, Zilvetti M, Friend P, Wood KJ. Recipient memory-like lymphocytes remain unresponsive to graft antigens after CAMPATH-H1 induction with reduced maintenance immunosuppression. Transplantation, 2006 82 : 1342.
8. Kirk AD, Cherikh WS, Ring M, et al. Dissociation of depletional induction and posttransplant lymphoproliferative disease in kidney recipients treated with alemtuzumab. Am J Transplant 2007 7 : 2619.